Back to Search
Start Over
Immune responses in liver-directed lentiviral gene therapy
- Source :
- Translational Research; Vol 161, Translational Research
- Publication Year :
- 2013
- Publisher :
- Elsevier BV, 2013.
-
Abstract
- The use of lentiviral vectors (LV)s for in vivo gene therapy is an ideal platform for treating many types of disease. Since LVs can transduce a wide array of cells, support long-term gene expression, and be modified to enhance cell targeting, LVs are a powerful modality to deliver life-long therapeutic proteins. A major limitation facing the use of LVs for in vivo gene therapy is the induction of immune responses, which can reduce the transduction efficiency of LV, eliminate the transduced cells, and inhibit the effect of the therapeutic protein. LV strategies designed to restrict transgene expression to the liver to exploit its naturally tolerogenic properties have proven to significantly reduce the induction of pathogenic immune responses and increase therapeutic efficacy. In this review, we outline the immunological hurdles facing in vivo LV gene therapy and highlight the advantages and limitations of using liver-directed LV gene therapy.
- Subjects :
- Genetic enhancement
Transgene
Biology
Viral vector
03 medical and health sciences
Transduction (genetics)
0302 clinical medicine
Immune system
Physiology (medical)
Immune Tolerance
Animals
Humans
Transgenes
Antigen-presenting cell
030304 developmental biology
0303 health sciences
Toll-like receptor
Lentivirus
Biochemistry (medical)
Immunity
Public Health, Environmental and Occupational Health
FOXP3
Genetic Therapy
General Medicine
3. Good health
Liver
030220 oncology & carcinogenesis
Immunology
Cancer research
Subjects
Details
- ISSN :
- 19315244
- Volume :
- 161
- Database :
- OpenAIRE
- Journal :
- Translational Research
- Accession number :
- edsair.doi.dedup.....0419fdd5e3257e24fd7c4b64f222ba91